ClinicalTrials.gg
RecruitingNCT07075588iTHRIVEUpdated Jun 30, 2026

Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure

An interventional study of iTHRIVE intervention and Active comparator in Hypertension and Hypertension Complicated With Type 2 Diabetes, sponsored by Johns Hopkins University. Recruiting at 3 sites in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.

Planned enrollment
28th of 44
100 · median 138
Started
2026
with 6 others
No phase
39 of 50
6 open now
Primary completion
2027-04
later than 7 of 13 live
Registered
44th of 50
by date

Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 28th largest by planned enrollment of the 44 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 44th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hypertension by Johns Hopkins University, or all of them as a file.
02

Study summary

iTHRIVE intervention is a 2-arm randomized controlled trial testing the effects of digital FARMacy, personalized dietitian coaching with produce prescriptions, and home blood pressure measurement in 100 hypertensive adults living in high food priority areas in counties in Maryland.

Read the detailed description

Cardiovascular-kidney-metabolic (CKM) syndrome is a devastating public health crisis that affects nearly 90% of US adults. CKM accounts for >30% of all US deaths and >5 million hospitalizations annually and imposes an annual economic burden of ≥$1 trillion, with a disproportionate impact on Black, Hispanic adults. Inequitable access to care, high-quality food, culturally tailored dietitian support, and living in "food deserts" (also known as Healthy Food Priority Areas (HFPAs) exacerbate CKM disparities. Innovative approaches are urgently needed to sustainably improve food access and CKM health of Black and Hispanic adults.

More than three times as many Black adults (31%) in Baltimore City live in HFPAs compared to White adults (9%). About 45% of households in Montgomery County earn less than the self-sufficiency standard, 64% of Supplemental Nutrition Assistance Program (SNAP)-eligible adults are unenrolled, the highest rate in MD. In 2022, 48% of Prince George's County residents lived in HFPAs. Reasons for these disparities are complex and comprise factors at the individual, provider, community, and systemic levels.

Evidence-based interventions that improve CKM health include personalized dietitian coaching, home blood pressure monitoring (HBPM), and culturally tailored messages. Digital interventions could improve access to dietitians and fruits/vegetables (f/v) through digital "FARMacy" (akin to a virtual farmers market). Implementation strategies for the delivery of these digital interventions are critical gaps, and clinic integration remains unclear. Digital FARMacy platforms offer potential for increased reach and engagement-relative effectiveness and implementation approach have not been explored.

The investigators propose to test the effects of iTHRIVE using a randomized controlled trial among 100 adult participants living in HFPAs in MD counties with uncontrolled BP defined as systolic blood pressure (SBP) ≥130 milimiters of mercury (mmHg) and diabetes or moderate risk chronic renal disease. Participants will be randomized to either iTHRIVE (digital FARMacy, personalized dietitian coaching with produce prescription [PRx], and HBPM) or enhanced usual care (EUC, general dietary advice, standard food bags). The investigators will assess the effectiveness of iTHRIVE in improving systolic blood pressure at 6 months and evaluate the reach, adoption, implementation, maintenance, and budget impact of iTHRIVE

03

Conditions studied

  • Hypertension
  • Hypertension Complicated With Type 2 Diabetes

Browse trials for

Keywords

  • Digital Farmacy
  • DASH Diet
  • Personalized dietitian coaching
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21-70 years
  • Self-identify as Black/African American or Hispanic/Latino
  • Have Stage 2 CKM defined as:
  • Systolic BP ≥130mmHg (measured at screening) AND at least one of:
  • Hypertension (ICD-10: I10-I16)
  • Prediabetes ( 5.7-6.4%) or Type 2 Diabetes (HbA1c ≥6.5%)
  • Stage 3 chronic kidney disease (CKD) ( 30-59 mL/min/1.73m²)
  • Live in census tracts identified by the Montgomery/ Prince George's/Baltimore City County Departments of Planning as HFPA:
  • Healthy Food Availability Index score is low (0-9.5),
  • Median household income ≤185% of Federal Poverty Level

    • 30% of households have no vehicle,
  • Distance to supermarket >1/4 mile. 5. Have refrigeration, food preparation appliances (microwave, stove), and cell phones for the App

Exclusion criteria

Exclusion Criteria:

  • Age \<21 years
  • Diagnosis of end-stage renal disease (ESRD), dialysis
  • Serious medical condition that either limits or requires active management (e.g., cancer)
  • Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence
  • Active alcohol or substance use disorder (i.e., not sober/abstinent for ≥ 30 days)
  • Patients with cognitive impairment or other condition preventing their participation in the intervention
  • Pregnant, breastfeeding, or planning pregnancy
  • Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation) or another clinical trial that could interfere with the study protocol
  • Planning to move out of the geographic area in 12 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    iTHRIVE intervention arm

    iTHRIVE intervention will include access to a digital produce prescription platform, virtual dietitian coaching, a Home blood pressure monitor with App integration, and produce

    Behavioral: iTHRIVE intervention

  • Active comparator
    Comparator Arm

    The active comparator arm will receive enhanced usual care, standard produce bags, general dietary advice, and a home blood pressure monitor

    Behavioral: Active comparator

Interventions

  • BehavioraliTHRIVE intervention

    Integration of three traditionally siloed components: 1. Digitally enabled food access 2. Personalized nutrition support 3. Clinical care-rision of home blood pressure device with app

  • BehavioralActive comparator

    Active comparator arm will receive enhanced usual care that consists of: 1. Standard produce bag 2. Home blood pressure Device without app 3. General dietary advice

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure (mmHg)

    Systolic blood pressure measured in millimeters of mercury (mmHg) by the home blood pressure device and in the electronic medical record (EMR)

    Time frame: Baseline, 3, 6 and 12 months

Secondary outcomes

  1. Hemoglobin A1c (percent)

    Hemoglobin A1c

    Time frame: Baseline, 3, and 6 months

  2. Weight in pounds

    Weight will be measured in pounds

    Time frame: Baseline, 3, 6, and 12 months

  3. Change in Dietary Patterns assessed by 24 hour dietary recall

    Change in Dietary Approaches to Stop Hypertension (DASH) adherence scores are summarized from 24-hour dietary recall administered by the investigator. Score range 0-9, higher scores indicate better adherence.

    Time frame: Baseline and 6 months

  4. Cost effectiveness

    Intervention cost/person will be estimated based on the total cost of the intervention and the estimated cost of treatment

    Time frame: Baseline and 12 weeks

  5. Cultural appropriateness and acceptability assessed by Cultural Sensitivity Assessment Tool

    Self-reported acceptance of Data Apps using Cultural Sensitivity Assessment Tool ( CSAT) with a score range of 1 to 4. A score of 2.5 is the cut-off score for acceptability

    Time frame: Baseline, 6 and 12 months

  6. Height in inches

    Height will be measured in inches

    Time frame: Baseline, 3,6 and 12months

07

Study locations

1 of 3 sites recruiting
  • Johns Hopkins Community Physicians
    Baltimore, Maryland 21205, United States
    Recruiting
  • Johns Hopkins School of Nursing
    Baltimore, Maryland 21205, United States
    Not yet recruiting
    • Mojisola Olusola-Bello, MD, MPH · Contactmolusol1@jh.edu · 240-540-4934
  • Holy Cross Hospital
    Gaithersburg, Maryland 20876, United States
    Not yet recruiting
    • Tosin Tomiwa · Contactthrive-fim@jh.edu · 410-873-7993
    • Erix Rivera · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 20, 2025
StartActual
Jun 25, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Mar 20, 2028
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075588
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jun 25, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Mar 20, 2028 (estimated)
Last update
Jun 30, 2026

Study contacts

Oluwabunmi Ogungbe, PhD, MPH, RN
Contact
oogungb3@jh.edu
410-614-1519
Yvonne Commodore-Mensah, PhD, MHS, RN
Contact
ycommod1@jhmi.edu
410614159
Oluwabunmi Ogungbe, PhD, MPH, RN
principal investigator · Johns Hopkins School of Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion